Categories: News

STARMED Unveils New Brand Identity to Drive Global Multi-Modality Strategy

SEOUL, South Korea, Jan. 8, 2026 /PRNewswire/ — STARMED, a pioneer in innovative minimally invasive treatment solutions, has announced a comprehensive rebranding. Now in its seventeenth year of operation, the company is formally transitioning from a Radiofrequency Ablation (RFA) specialist into a global multi-modality medical technology platform.

- Advertisement -

Established in 2009, STARMED pioneered the first thyroid-dedicated RFA electrode, effectively creating a clinical field that did not previously exist. This technology has since been adopted into various international clinical guidelines and continues to maintain the leading global market share today. Building on this heritage, STARMED has expanded its portfolio to address diverse clinical needs in liver, uterine, and vascular care, introducing various products such as the proprietary multi-electrode Octopus system. The current rebranding signals a strategic commitment to expand beyond RFA by integrating diverse energy sources, including Microwave Ablation (MWA) and Irreversible Electroporation (IRE), into a unified therapeutic offering.

- Advertisement -

“With the global thermal ablation market projected to reach $2 billion by 2033, this rebranding is a pivotal step for our next stage of growth,” said CEO Henry Shin.

- Advertisement -

The newly unveiled Corporate Identity reflects both STARMED’s heritage and its future vision. The symbol represents technical precision by visualising the initial ‘S’ alongside the silhouette of an electrode tip. This reflects a dedication to minimising patient pain and providing care throughout the recovery process. The wordmark employs a sophisticated, futuristic typeface to reinforce trust within the global healthcare arena.

- Advertisement -

Supported by strong financial foundations, STARMED plans to capitalise on a market growing at 10.5% annually. The company remains committed to establishing minimally invasive treatments as the global ‘Standard of Care’ through enhanced clinical partnerships.

- Advertisement -

About STARMED

- Advertisement -

STARMED is a medical device specialist founded in 2009. With more than 660 clinical research evidence, the company provides world-class thermal ablation solutions to over 70 countries and continues to advance minimally invasive treatment as the clinical standard.

- Advertisement -

Photo – https://mma.prnewswire.com/media/2857156/STARMED_800px.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/starmed-unveils-new-brand-identity-to-drive-global-multi-modality-strategy-302655927.html

- Advertisement -

Recent Posts

Dalton Pharma Services Expands Aseptic Powder Fill-Finish Capacity with RoboFil system in Toronto

A fully automated aseptic fill-finish platform delivers greater speed, flexibility, and quality for the manufacturing…

1 hour ago

Deakin University advances global agenda for affordable health through RAAH Roundtable

NEW DELHI, March 31, 2026 /PRNewswire/ -- Deakin University, Australia, ranked among the top 1%…

1 hour ago

SirPAD: Primary Results confirm the safety and efficacy of Sirolimus Coated Balloon in PAD

TAMPA, Fla., March 31, 2026 /PRNewswire/ -- Concept Medical Inc. (CMI), a global leader in…

1 hour ago

DNV SELECTED TO CERTIFY CLASS D DEVICES FOR LEADING U.S. MANUFACTURER UNDER EU IVDR

DNV supports the manufacturer's transition to new regulation with its digital certification platform and transparent,…

1 hour ago

BioAtla Announces Share Consolidation

March 31, 2026 16:06 ET  | Source: BioAtla, Inc. SAN DIEGO, March 31, 2026 (GLOBE…

4 hours ago

Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

– Released positive topline data from Phase 1 study of IV rademikibart in patients with…

4 hours ago